Objective:To investigate the effects of tetramethylpyrazine(TMP)on spinal cord inflammation and phosphatidylinositol 3-kinase/serine-threonine kinase/nuclear factor-κB(PI3K/Akt/NF-κB)signaling pathway in rats with lumbar disc herniation(LDH).Methods:The rats were divided into Control group,lumbar disc herniation group(LDH group),TMP low-dose,high-dose group(TMP-L,TMP-H group),TMP high-dose+PI3K inhibitor group(TMP-H+LY294002 group)by random number table method.LDH rat model was established by autologous nucleus pulposus transplantation and treated with corresponding drugs.After administration,the pain threshold of rats in each group was measured by paw tactile tester and plantar thermal stimulation tester.Hematoxylin-eosin(HE)staining was used to observe the histomorphological changes of dorsal root ganglion.Enzyme linked immunosorbent assay(ELISA)was used to measure the levels of tumor necrosis factor α(TNF-α),interleukin-1β(IL-1β)and interleukin-6(IL-6)in the spinal dorsal horn.Immunohistochemistry was used to detect the expression of ionized calcium binding adapter molecule 1(Iba-1)and c-Fos in the spinal dorsal horn.Western blot was used to detect the expression of PI3K/Akt/NF-κB signaling pathway related proteins,and the ratios of p-PI3K/PI3K,p-Akt/Akt and p-NF-κB p65/NF-κB p65 were calculated.Results:At 24h before intervention,the paw withdrawal mechanical threshold(PWMT)and paw withdrawal thermal latency(PWTL)in the LDH group were lower than those in the Control group(P<0.05).At 24h after intervention,compared with Control group,the LDH group had severe nucleus deviation,blurred nucleoli,large amount of inflammatory cell infiltration and obvious cell swelling,decreased PWMT,PWTL,p-PI3K/PI3K and p-Akt/Akt,and increased levels of TNF-α,IL-1β,IL-6 and Iba-1,c-Fos and p-NF-κB p65/NF-κB p65(P<0.05).Com-pared with the LDH group,the neurons had less nuclear deviation,clearer nucleoli,less cell swelling and inflammatory cell infiltration in the TMP-L group and TMP-H group,and the PWMT,PWTL,p-PI3K/PI3K and p-Akt/Akt were in-creased in turn,while the levels of TNF-α,IL-1β,IL-6 and Iba-1,c-Fos,p-NF-κB p65/NF-κB p65 were decreased in turn(P<0.05).Compared with the TMP-H group,the TMP-H+LY294002 group had more severe pathological dam-age of neurons,obvious nuclear deviation,blurred nucleoli,cell swelling and inflammatory cell infiltration,decreased PWMT,PWTL,p-PI3K/PI3K and p-Akt/Akt,and increased levels of TNF-α,IL-1β,IL-6 and Iba-1,c-Fos and p-NF-κB p65/NF-κB p65(P<0.05).Conclusion:TMP can inhibit the activation of microglia and the expression of Iba-1 and c-Fos,and improve spinal cord inflammation in LDH rats,and its mechanism may be related to the regulation of PI3K/Akt/NF-κB signaling pathway.

Objective:To develop and validate a novel PET tracer, N-cyclohexyl-4-((2, 4-dichlorophenyl)(4-(fluoro- 18F)phenyl)methyl)piperazine-1-carboxamide ( 18F-SQKJ-2), targeting cannabinoid type 1 (CB1) receptors for diagnosing psychiatric disorders associated with fear memory. Methods:18F-SQKJ-2 was prepared using a nucleophilic substitution radiochemical synthesis method. For the CB1 receptor blocking experiment, 7 ICR mice were divided into blocking group ( n=4; rimonabant for blocking treatment) and control group 1 ( n=3; no rimonabant blocking treatment). The affinity and specificity of 18F-SQKJ-2 for CB1 receptors were analyzed based on the differences in 18F-SQKJ-2 uptake (percentage injected dose per gram of tissue, %ID/g) by various organs between two groups. The metabolic stability of 18F-SQKJ-2 in vitro was studied using animal tissue homogenates. Ten C57 mice were used to establish fear memory mouse models (fear group, n=6; control group 2, n=4), and the percentage of freezing time was compared between 2 groups. MicroPET scans were used to detect the intracranial distribution of 18F-SQKJ-2, and the relative uptake in each brain region compared to total brain uptake was calculated. Statistical analysis was conducted to compare the differences in CB1 receptor relative total brain uptake in fear-related brain regions between 2 groups. Independent-sample t test and Mann-Whitney U test were used to analyze the data. Results:18F-SQKJ-2 was successfully synthesized with a radiochemical purity ≥98.0% and a corrected radioactive yield of (12.3±6.0)%( n=4). In vitro metabolic stability experiments showed that 18F-SQKJ-2 was basically stable in the liver, blood, and brain within 60min. The CB1 receptor blocking experiment demonstrated that the uptake of 18F-SQKJ-2 in the brains of mice in blocking group was significantly lower than that in control group 1 ((0.95±0.28) vs (3.44±1.16) %ID/g; t=-3.57, P=0.023). The percentage of freezing time in fear group was significantly higher than that in control group 2 (43.28%(39.46%, 52.93%) vs 2.74%(1.52%, 4.85%); Z=-2.45, P=0.010). 18F-SQKJ-2 microPET imaging showed that the uptake of 18F-SQKJ-2 in the cerebral cortex of mice in fear group was significantly increased compared with that in control group 2 ((5.83±0.47)% vs (5.00±0.52)%; t=2.42, P=0.046). Conclusion:18F-SQKJ-2 is successfully prepared with acceptable radiochemical purity and metabolic stability, demonstrating potential for visualizing and quantifying fear memory.

The prevalence of Class III malocclusion varies among different countries and regions. The populations from Southeast Asian countries (Chinese and Malaysian) showed the highest prevalence rate of 15.8%, which can seriously affect oral function, facial appearance, and mental health. As anterior crossbite tends to worsen with growth, early orthodontic treatment can harness growth potential to normalize maxillofacial development or reduce skeletal malformation severity, thereby reducing the difficulty and shortening the treatment cycle of later-stage treatment. This is beneficial for the physical and mental growth of children. Therefore, early orthodontic treatment for Class III malocclusion is particularly important. Determining the optimal timing for early orthodontic treatment requires a comprehensive assessment of clinical manifestations, dental age, and skeletal age, and can lead to better results with less effort. Currently, standardized treatment guidelines for early orthodontic treatment of Class III malocclusion are lacking. This review provides a comprehensive summary of the etiology, clinical manifestations, classification, and early orthodontic techniques for Class III malocclusion, along with systematic discussions on selecting early treatment plans. The purpose of this expert consensus is to standardize clinical practices and improve the treatment outcomes of Class III malocclusion through early orthodontic treatment.
Humans ; Malocclusion, Angle Class III/classification* ; Orthodontics, Corrective/methods* ; Consensus ; Child

Objective:To develop and validate a novel PET tracer, N-cyclohexyl-4-((2, 4-dichlorophenyl)(4-(fluoro- 18F)phenyl)methyl)piperazine-1-carboxamide ( 18F-SQKJ-2), targeting cannabinoid type 1 (CB1) receptors for diagnosing psychiatric disorders associated with fear memory. Methods:18F-SQKJ-2 was prepared using a nucleophilic substitution radiochemical synthesis method. For the CB1 receptor blocking experiment, 7 ICR mice were divided into blocking group ( n=4; rimonabant for blocking treatment) and control group 1 ( n=3; no rimonabant blocking treatment). The affinity and specificity of 18F-SQKJ-2 for CB1 receptors were analyzed based on the differences in 18F-SQKJ-2 uptake (percentage injected dose per gram of tissue, %ID/g) by various organs between two groups. The metabolic stability of 18F-SQKJ-2 in vitro was studied using animal tissue homogenates. Ten C57 mice were used to establish fear memory mouse models (fear group, n=6; control group 2, n=4), and the percentage of freezing time was compared between 2 groups. MicroPET scans were used to detect the intracranial distribution of 18F-SQKJ-2, and the relative uptake in each brain region compared to total brain uptake was calculated. Statistical analysis was conducted to compare the differences in CB1 receptor relative total brain uptake in fear-related brain regions between 2 groups. Independent-sample t test and Mann-Whitney U test were used to analyze the data. Results:18F-SQKJ-2 was successfully synthesized with a radiochemical purity ≥98.0% and a corrected radioactive yield of (12.3±6.0)%( n=4). In vitro metabolic stability experiments showed that 18F-SQKJ-2 was basically stable in the liver, blood, and brain within 60min. The CB1 receptor blocking experiment demonstrated that the uptake of 18F-SQKJ-2 in the brains of mice in blocking group was significantly lower than that in control group 1 ((0.95±0.28) vs (3.44±1.16) %ID/g; t=-3.57, P=0.023). The percentage of freezing time in fear group was significantly higher than that in control group 2 (43.28%(39.46%, 52.93%) vs 2.74%(1.52%, 4.85%); Z=-2.45, P=0.010). 18F-SQKJ-2 microPET imaging showed that the uptake of 18F-SQKJ-2 in the cerebral cortex of mice in fear group was significantly increased compared with that in control group 2 ((5.83±0.47)% vs (5.00±0.52)%; t=2.42, P=0.046). Conclusion:18F-SQKJ-2 is successfully prepared with acceptable radiochemical purity and metabolic stability, demonstrating potential for visualizing and quantifying fear memory.

This consensus was developed by the Orthodontic Society of the Chinese Stomatological Association to provide a systematic, scientific, and practical guideline for informed consent in orthodontic care. Orthodontic treatment is typically lengthy, highly individualized, and involves multiple factors such as growth and development, occlusal function, and facial esthetics. Rapid technological advances and diverse risk profiles make the traditional reliance on orthodontist experience or institutional templates insufficient to ensure patients′ full understanding and autonomous decision-making. To address this, the expert panel conducted extensive reviews of domestic and international guidelines, analyzed representative dispute cases, and performed multicenter patient-clinician surveys. Using a multi-round Delphi method, the group established a standardized informed consent framework covering the initial consultation, treatment, and retention phases. The consensus emphasizes that informed consent is not only a fundamental legal and ethical requirement but also a key step in building trust, improving patient compliance, and enhancing treatment satisfaction. Orthodontists should clearly and comprehensively explain treatment plans, potential risks, uncertainties, and associated costs, while respecting the autonomy of patients or guardians, and maintain continuous communication and dynamic evaluation throughout the treatment process. The release of this consensus provides unified and authoritative guidance for clinical orthodontics, helping to standardize informed consent, enhance its transparency, safeguard patient rights, reduce medical risks, and promote high-quality, sustainable development of orthodontic practice.

This consensus was developed by the Orthodontic Society of the Chinese Stomatological Association to provide a systematic, scientific, and practical guideline for informed consent in orthodontic care. Orthodontic treatment is typically lengthy, highly individualized, and involves multiple factors such as growth and development, occlusal function, and facial esthetics. Rapid technological advances and diverse risk profiles make the traditional reliance on orthodontist experience or institutional templates insufficient to ensure patients′ full understanding and autonomous decision-making. To address this, the expert panel conducted extensive reviews of domestic and international guidelines, analyzed representative dispute cases, and performed multicenter patient-clinician surveys. Using a multi-round Delphi method, the group established a standardized informed consent framework covering the initial consultation, treatment, and retention phases. The consensus emphasizes that informed consent is not only a fundamental legal and ethical requirement but also a key step in building trust, improving patient compliance, and enhancing treatment satisfaction. Orthodontists should clearly and comprehensively explain treatment plans, potential risks, uncertainties, and associated costs, while respecting the autonomy of patients or guardians, and maintain continuous communication and dynamic evaluation throughout the treatment process. The release of this consensus provides unified and authoritative guidance for clinical orthodontics, helping to standardize informed consent, enhance its transparency, safeguard patient rights, reduce medical risks, and promote high-quality, sustainable development of orthodontic practice.

Objective:To investigate the effects of tetramethylpyrazine(TMP)on spinal cord inflammation and phosphatidylinositol 3-kinase/serine-threonine kinase/nuclear factor-κB(PI3K/Akt/NF-κB)signaling pathway in rats with lumbar disc herniation(LDH).Methods:The rats were divided into Control group,lumbar disc herniation group(LDH group),TMP low-dose,high-dose group(TMP-L,TMP-H group),TMP high-dose+PI3K inhibitor group(TMP-H+LY294002 group)by random number table method.LDH rat model was established by autologous nucleus pulposus transplantation and treated with corresponding drugs.After administration,the pain threshold of rats in each group was measured by paw tactile tester and plantar thermal stimulation tester.Hematoxylin-eosin(HE)staining was used to observe the histomorphological changes of dorsal root ganglion.Enzyme linked immunosorbent assay(ELISA)was used to measure the levels of tumor necrosis factor α(TNF-α),interleukin-1β(IL-1β)and interleukin-6(IL-6)in the spinal dorsal horn.Immunohistochemistry was used to detect the expression of ionized calcium binding adapter molecule 1(Iba-1)and c-Fos in the spinal dorsal horn.Western blot was used to detect the expression of PI3K/Akt/NF-κB signaling pathway related proteins,and the ratios of p-PI3K/PI3K,p-Akt/Akt and p-NF-κB p65/NF-κB p65 were calculated.Results:At 24h before intervention,the paw withdrawal mechanical threshold(PWMT)and paw withdrawal thermal latency(PWTL)in the LDH group were lower than those in the Control group(P<0.05).At 24h after intervention,compared with Control group,the LDH group had severe nucleus deviation,blurred nucleoli,large amount of inflammatory cell infiltration and obvious cell swelling,decreased PWMT,PWTL,p-PI3K/PI3K and p-Akt/Akt,and increased levels of TNF-α,IL-1β,IL-6 and Iba-1,c-Fos and p-NF-κB p65/NF-κB p65(P<0.05).Com-pared with the LDH group,the neurons had less nuclear deviation,clearer nucleoli,less cell swelling and inflammatory cell infiltration in the TMP-L group and TMP-H group,and the PWMT,PWTL,p-PI3K/PI3K and p-Akt/Akt were in-creased in turn,while the levels of TNF-α,IL-1β,IL-6 and Iba-1,c-Fos,p-NF-κB p65/NF-κB p65 were decreased in turn(P<0.05).Compared with the TMP-H group,the TMP-H+LY294002 group had more severe pathological dam-age of neurons,obvious nuclear deviation,blurred nucleoli,cell swelling and inflammatory cell infiltration,decreased PWMT,PWTL,p-PI3K/PI3K and p-Akt/Akt,and increased levels of TNF-α,IL-1β,IL-6 and Iba-1,c-Fos and p-NF-κB p65/NF-κB p65(P<0.05).Conclusion:TMP can inhibit the activation of microglia and the expression of Iba-1 and c-Fos,and improve spinal cord inflammation in LDH rats,and its mechanism may be related to the regulation of PI3K/Akt/NF-κB signaling pathway.

Objective:To compare the influence of dronedarone and amiodarone on the bleeding risk of patients with atrial fibrillation treated with rivaroxaban anticoagulation.Methods:Clinical data of 81 patients with atrial fibrillation treated with rivaroxaban anticoagulation at Xi'an International Medical Center Hospital from January 2020 to July 2023, including 36 patients treated with dronedarone and 45 patients treated with amiodarone, were retrospectively analyzed. The effects of dronedarone and amiodarone on the anticoagulation of rivaroxaban were compared using the incidence of bleeding events, thrombosis events, and adverse reactions as outcome measures.Results:The total bleeding in the dronedarone group [22.22% (8/36)] was significantly higher than that in the amiodarone group [6.67% (3/45)] ( χ2 = 4.12, P < 0.05). The total bleeding of conventional-dose rivaroxaban in the dronedarone group was 30.00% (6/20), while the total bleeding of low-dose rivaroxaban was 12.50% (2/16), with no statistical significance ( χ2 = 1.58, P > 0.05). No thrombotic events or adverse reactions to dronedarone or amiodarone were observed in all patients. Conclusion:Compared with amiodarone, dronedarone significantly increases the bleeding risk of rivaroxaban anticoagulation in patients with non-valvular atrial fibrillation, and reducing the dose of rivaroxaban in patients using dronedarone does not reduce the bleeding risk.

OBJECTIVE To investigate the improvement effect and mechanism of triptolide （TP） on sciatica rats. METHODS Sciatica rat model was prepared and then randomly divided into model group （normal saline）， indomethacin group （positive control， 7.5 mg/kg）， TP low-dose and high-dose groups （TP-L group and TP-H group， 50， 100 μg/kg TP）， and high-dose TP+ stimulator of interferon gene （STING） activator group （TP-H+DMXAA group， 100 μg/kg TP+25 mg/kg DMXAA）， with 12 rats in each group. Another 12 unligated rats were selected as sham operation group （normal saline）. After 14 days of intraperitoneal administration， the paw mechanical withdrawal threshold （PWT） and paw withdrawal thermal latency （PWL） were detected； the pathological changes， morphology of sciatic nerve and the number of microglia in sciatic nerve were observed. The levels of interleukin-1β （IL-1β） and tumor necrosis factor-α （TNF-α）， mRNA and protein expression levels of cyclic guanosine monophosphate- adenosine monophosphate synthase （cGAS） and STING in sciatic nerve were detected. RESULTS Compared with sham operation group， PWT and PWL of rats in model group were obviously reduced and shortened， the number of Nissl bodies was obviously decreased， while the number of microglia， sciatic neuropathology score， the levels of IL-1β and TNF-α， mRNA and protein expressions of cGAS and STING were obviously increased （P＜0.05）， and sciatic nerve injury was serious. Compared with model group， the changes of various indexes in indomethacin group， TP-L group and TP-H group were opposite to the above （P＜0.05）， and sciatic nerve injury was reduced. STING activator DMXAA weakened the inhibitory effect of TP on the activity of microglia and inflammatory response in sciatica rats （P＜0.05）. CONCLUSIONS TP may reduce the activity of microglia and inflammatory response by down-regulating the cGAS/STING signaling pathway， thus alleviating sciatica in rats.

Objective:To investigate the effect of anoxic cold environment at 4500 m altitude on female men-struation.Methods:From March 1 to March 20,2023,women in a unit at an altitude of 4500 meters were selected for reproductive health questionnaire survey,and were divided into≤6 months group,6 months to 12 months group and≥12 months group according to altitude exposure time.The changes of menstruation in each group were analyzed to explore the relevant influencing factors.Results:The total incidence of abnormal menstruation in working women in hypoxic cold environment was as high as 66.14%,and there was no statistically significant difference between the groups at different high-altitude exposure times(P＞0.05).The highest incidence of dys-menorrhea among the types of menstrual changes was 61.90%,but there was no statistically significant differ-ence between the groups at different high altitude exposure times(P＞0.05).There was a statistically significant difference(P＜0.05)in the proportion of insufficient sleep for at least 3 days per week,nervousness and anxiety,and training during their menstrual period in the women who experienced changes in their menstrual cycle com-pared to those who did not.Conclusions:Hypoxic cold environment can lead to the change of female menstrua-tion,and it is combined with sleep deficiency,tension and anxiety,and menstrual exercise.